Interferon Beta-1A: 4 agencies, 2002–2017
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
No agency in this archive has refused interferon beta-1a: all 5 decisive outcomes across 2 agencies were positive or positive with restrictions.
The file has been open for more than a decade: 15 years separate the first record, 23 Jan 2002 at AWMSG (Wales), from the most recent, 11 Jan 2017 at HAS (France).
No assessment is on file from PBAC (Australia), PHARMAC (New Zealand), CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
Not every gap is a refusal: for interferon beta-1a, 1 submission was never made — an outcome set by the company rather than the assessor.
Nothing has been added since 2017; on this evidence the file is dormant.
3 distinct indication wordings are recorded for interferon beta-1a by the agencies that label one in English (AWMSG and SMC).
AWMSG (Wales) was first to assess interferon beta-1a, on 23 Jan 2002; SMC (Scotland) did not open a file until 12 Nov 2012 — an unusually long tail of 10.8 years between the earliest and latest system to look at it.
The record arrives in waves: 4 separate years each carry two or more decisions, spread across 9 years in total.
3 of the 4 agencies here assessed interferon beta-1a more than once, HAS (France) most often at 9 entries — repeat review is the norm for this molecule rather than the exception.
Coverage is narrow: only 4 of the 18 agencies here have assessed interferon beta-1a.
The full ledger for interferon beta-1a reads 7 other, 5 recommended, 1 non-submission and 1 superseded, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| HAS (France) | 11 Jan 2017 | Listing renewal (Transparency Committee) | SMR substantial | source |
| HAS (France) | 5 Oct 2016 | Listing renewal (Transparency Committee) | SMR substantial | source |
| SMC (Scotland) | 12 Nov 2012 | Patients with a single demyelinating event with an active inflammatory process, if alternative diagnoses have been excluded, and if they are determined to be at high risk… | not recommended | source |
| AWMSG (Wales) | 19 Jun 2012 | Treatment of patients with a single demyelinating event with an active inflammatory process | superseded (non-submission) | source |
| TLV (Sweden) | 12 Oct 2011 | Ny form av Avonex, AvonexPen, ingår i högkostnadsskyddet | general subsidy | source |
10 further decisions for interferon beta-1a, across 3 agencies, are not shown here. They link to 8 further source documents.
Related molecules
- filgrastim — same ATC class L03A — Immunostimulants
- pegfilgrastim — same ATC class L03A — Immunostimulants
- peginterferon alfa-2a — same ATC class L03A — Immunostimulants
- plerixafor — same ATC class L03A — Immunostimulants
- glatiramer — same ATC class L03A — Immunostimulants
- ropeginterferon alfa-2b — same ATC class L03A — Immunostimulants
Coverage: 15 decisions for interferon beta-1a from 4 agencies, 2002 to 2017. Data to 7 Sep 2026. ATC class L03A — Immunostimulants. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.